Galapagos creates new warrant plan
January 20 2017 - 4:04PM
Mechelen, Belgium; 20 January 2017 - Galapagos
NV (Euronext & NASDAQ: GLPG) announced today that its
Board of Directors created 150,000 warrants under a new
warrant plan for the benefit of an employee of a subsidiary of the
Company.
On 20 January 2017, the Board of Directors of
Galapagos approved the "Warrant Plan 2016 (B)," a warrant plan
intended for an employee of a subsidiary of the Company, within the
framework of the authorized capital. Under this warrant plan,
150,000 warrants were created (subject to acceptance) and offered
to Dr. Walid Abi-Saab, who will start March 1 at Galapagos as Chief
Medical Officer.
The warrants have an exercise term of eight
years as of the date of the offer and have an exercise price of
€62.50 (the closing price of Galapagos' shares on Euronext
Amsterdam and Brussels on the last trading day preceding the date
of the offer). The warrants are not transferable and can in
principle not be exercised prior to the third anniversary of their
issuance. Each warrant gives the right to subscribe to one new
Galapagos share. Should the warrants be exercised, Galapagos will
apply for the listing of the resulting new shares on a regulated
stock market. The warrants as such will not be listed on any stock
market.
Galapagos' total share capital currently amounts
to €250,187,166.48; the total number of securities conferring
voting rights is 46,256,078, which is also the total number of
voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The
total number of rights (warrants) to subscribe to not yet issued
securities conferring voting rights is 3,466,407, which equals the
total number of voting rights that may result from the exercise of
these warrants, and excludes the 150,000 warrants of Warrant
Plan 2016 (B) which were created subject to acceptance.
Galapagos does not have any convertible bonds or shares without
voting rights outstanding.
About Galapagos Galapagos (Euronext &
NASDAQ: GLPG) is a clinical-stage biotechnology company specialized
in the discovery and development of small molecule medicines with
novel modes of action. Our maturing pipeline comprises Phase 3,
Phase 2, Phase 1, pre-clinical and discovery studies in cystic
fibrosis, inflammation, fibrosis, osteoarthritis and other
indications. We have discovered and developed filgotinib: in
collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the
world. Galapagos is focused on the development and
commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service subsidiary
Fidelta, has approximately 480 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands,
France, and Croatia. More information at www.glpg.com.
CONTACT
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn
Fox |
VP IR
& CorporateCommunications+1 781 460 1784 |
Director
Communications+31 6 53 591 999communications@glpg.com |
Paul van der HorstDirector IR & BusinessDevelopment+31 6 53 725
199 |
|
ir@glpg.com |
|
Forward-looking statementsThis release
may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but
not always, made through the use of words or phrases such as
"anticipates," "believes," "continues," "could," "estimates,"
"expects," "intends," "may," "plans," "seeks," "stands to," "we
believe," "will," "we intend," as well as similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition and liquidity, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent
with such forward-looking statements, they may not be predictive of
results or developments in future periods. Among the factors that
may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements
(including that data from Galapagos' ongoing clinical research
programs may not support registration or further development of its
product candidates due to safety, efficacy or other reasons),
Galapagos' reliance on collaborations with third parties, and
estimating the commercial potential of Galapagos' product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in Galapagos' Securities
and Exchange Commission (SEC) filings and reports, including in
Galapagos' most recent annual report on form 20-F filed with the
SEC and subsequent filings and reports filed by Galapagos with the
SEC. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking
statements, unless specifically required by law or regulation.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/db007f6e-799e-488e-81e9-54c59da51e9c
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024